MCL1 and neoplasm: The addition of AMG 176 to sotorasib led to greater tumor response than sotorasib alone in LKB1-deficient PDX tumors with MCL-1-dependent priming but not LKB1-deficient PDX tumors (Fig. 6E, F, S12C, D).